Overview

R-2487 in Patients With Rheumatoid Arthritis

Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Phase:
Phase 1
Details
Lead Sponsor:
Rise Therapeutics LLC